For example, Huttner and colleagues demonstrated in a series of publications that CD133+ EVs associated with cerebrospinal fluid can be used as a biomarker to monitor neural diseases such as cancer or brain injury [294–297]. This evidence concerns the gene PROM1 and cancer.